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Recent genetic evidence in humans and from mouse knockouts has linked kisspeptin-driven GPR54 signaling to the
regulation of GnRH release from the hypothalamus. These molecules appear to represent a previously unsuspected control
point for GnRH secretion, with important implications for the biology and pathology of the sex steroid axis.The gonadotropic drive of gonadal function is subject to com-
plex regulation by the hypothalamic-pituitary axis. Central in
the hormonal cascade is the pulsatile release of gonadotropin-
releasing hormone (GnRH) from neurons in the hypothalamus
(see Figure 1). In mammals, increasing amplitude pulsatile re-
lease of GnRH marks the onset of puberty and is the driver for
postpubertal gonadal functions. However, the precise mecha-
nisms of GnRH pulsatility and, crucially, its developmental tem-
poral regulation, have remained enigmatic despite intensive in-
vestigation over the 30 years since GnRH was discovered. In
the last decade, attention has focused on neuronal and meta-
bolic inputs (such as NMDA, leptin, and NP-Y signaling) to the
hypothalamus in the search for regulating factors; however, the
presence of a fundamental neuropeptide hormone-releasing
and/or driver system for GnRH itself had eluded discovery.
Such a system may now have been found, with recent human
and mouse genetics studies (de Roux et al., 2003; Seminara et
al., 2003; Semple et al., 2004) on signaling through the galanin-
related G protein-coupled receptor GPR54 and subsequent
work (Gottsch et al., 2004; Irwig et al., 2004; Irwig et al., 2005;
Matsui et al., 2004; Messager et al., 2005; Navarro et al.,
2004a; Navarro et al., 2005a; Navarro et al., 2005b; Navarro et
al., 2004b; Shahab et al., 2005; Thompson et al., 2004) on the
RF-amide peptide ligands known canonically as kisspeptins.
The key observations were made with the discovery that
loss-of-function mutations in GPR54 in humans and mice
(Seminara et al., 2003) result in phenocopy syndromes of iso-
lated hypothalamic hypogonadism (IHH). These studies re-
vealed that mice and humans lacking GPR54 fail to drive pitu-
itary gonadotrope secretion of LH/FSH, although, in both
cases, gonadotropes remain functionally capable of respond-
ing to exogenous GnRH. Analysis of the mouse mutants of
GPR54 also showed that GnRH is synthesized normally in hy-
pothalamic GnRH neurons, and more recent work (Messager
et al., 2005) has demonstrated this is not due to a major mismi-
gration of neurons, as occurs in patients with KAL1 and FGFR1
mutations (see Seminara and Crowley [2001] for review). High-
affinity ligands (approximately 2 nM EC50) for GPR54 are
known and are the product of the KISS1 locus, deriving from
cleavage of a 145 residue RF-amide propeptide, by incom-
pletely defined propeptide processing enzymes (Clements et
al., 2001; Kotani et al., 2001; Muir et al., 2001; Ohtaki et al.,CELL METABOLISM : MAY 2005 · VOL. 1 · COPYRIGHT © 2005 ELSEVIE2001). The major circulating and tissue form of kisspeptin is a
54 residue fragment (also known as metastin), although shorter
fragments of between 10 and 14 residues also occur naturally
and appear to be as potent as kisspeptin-54. Since the genet-
ics defined GPR54 as required at the level of GnRH neurons
and/or on neurons regulating GnRH neurons, this strongly im-
plied that kisspeptin-driven GPR54 signaling could act as a
direct releasing mechanism for GnRH. This model has now re-
ceived support from two sets of observations: first, that GPR54
is colocalized on GnRH neurons (Irwig et al., 2004; Messager et
al., 2005) (an arrangement conserved in teleost GnRH neurons
[Parhar et al., 2004]); second, a releasing effect of peripheral
and central kisspeptin administration on GnRH has been
shown directly (Messager et al., 2005) and indirectly (Matsui et
al., 2004; Navarro et al., 2004a; Navarro et al., 2004b) (as well
as in isolated hypothalamic tissue explants [Thompson et al.,
2004]) and is associated with c-fos induction in GnRH neurons
(Irwig et al., 2004; Matsui et al., 2004). Furthermore, as sug-
gested by the high affinity of kisspeptides for GPR54, the
GnRH-releasing effects of injected kisspeptides are GPR54 de-
pendent, since mutant GPR54 mice fail to respond to repeated
kisspeptin administration (Messager et al., 2005). Thus, a
mechanism for the actions of kisspeptin-GPR54 signaling
(summarized in Figure 1) has emerged—namely, that GPR54
activation by kisspeptins results directly in GnRH release from
hypothalamic GnRH neurons. This mechanism poses a number
of currently unresolved questions.
During neonatal life and early postnatal life, the GnRH axis
is active but then becomes dormant during childhood and ado-
lescence. The reactivation of the axis, manifest as increasing
amplitude of GnRH pulses, is the trigger for puberty. The pre-
cise mechanisms regulating this “juvenile pause” remain ob-
scure; however, kisspeptins and GPR54 are now prime candi-
dates for a role in this process. There is evidence that KISS1
transcripts and GPR54 transcripts are upregulated in the hypo-
thalamus at the time of puberty (Navarro et al., 2004a; Shahab
et al., 2005). Furthermore, one recent study (Navarro et al.,
2004b) has shown that the onset of puberty in rodents can
be advanced with chronic kisspeptin administration. Given the
direct GnRH releasing effects for GPR54 described above, this
is not surprising. However, the question that remains is whether
modulation of kisspeptin expression occurs during neonatal lifeR INC. DOI 10.1016/j.cmet.2005.04.001 293
M I N I R E V I E WFigure 1. Overview of the hypothalamic-pituitary-gonadal axis
(Left panel) Release of LH/FSH acts on receptors in the gonads to drive steroidogenesis and stimulate gamete maturation. Sex steroids from the gonads exert feedback
regulation on the hypothalamus and pituitary, together with inhibin and other peptides released from the gonads (data not shown). (Right panel) GnRH-containing
neurons release GnRH (green) from terminals at the median eminence into the portal hypophseal circulation (red), where it acts on GnRH receptors (green) on
gonadotropes in the pituitary. GPR54 receptors (orange) are coexpressed on GnRH neurons, although it is unknown whether this is only on dendrites or also at the
terminals in the median eminence. The release on GnRH (arrowed) is pulsatile, and varying pulse amplitude regulates the pituitary. Kisspeptins (yellow circles) from the
periphery or released locally from hypothalamic neuronal terminals act on GPR54 receptors to cause GnRH release.and furthermore whether some developmental change in ex-
pression of GPR54/kisspeptin is in fact the maturational trigger
for high-amplitude pulsatile GnRH release.
Following directly from this question arises another—what
are the sources of kisspeptins, and do they (only) act on GnRH
neurons locally as neuroendocrine mediators or do they also
act from a peripheral source? Kisspeptins have been shown to
be present in hypothalamic neurons of primates and rodents.
Furthermore, KISS1 transcription appears to be subject to
moderate upregulation after castration (implying negative feed-
back from sex steroids) (Navarro et al., 2004a; Shahab et al.,
2005) and covaries with the estrus cycle. Thus, a local neuro-
endocrine mechanism of action is entirely plausible; however,
the precise neuronal populations that could be involved have
yet to be described in detail. A related but currently unresolved
question is whether GPR54 receptor signaling works via a re-
lease at the median eminence terminals and/or via localization
of the receptor elsewhere on GnRH neuron cell bodies.
In additional to neuronal sources, it is also clear that kisspep-294tins can be produced from the periphery (Figure 2). In preg-
nancy, serum levels of placental-derived kisspeptin-54 rise
10,000-fold above nonpregnant levels by the third trimester
(Horikoshi et al., 2003). From the peptide administration experi-
ments described above, it appears that kisspeptins can act
from the periphery, either by crossing the blood-brain barrier
and/or by acting directly on GnRH neuronal terminals at the
hypothalamic median eminence (which lies outside the blood-
brain barrier). At present however, there are no data to show
whether peripherally derived kisspeptin is required for any ma-
jor physiological regulatory action on the hypothalamus, either
in pregnancy or in other physiological states. Perhaps placen-
tal-derived kisspeptins play a role in allowing continued gonad-
otropin secretion, despite high sex steroid levels in pregnancy.
The possibility of pituitary comodulation of GnRHR signaling
by GPR54 also remains formally open. The fact that both hu-
mans and mice deficient in GPR54 remain capable of function-
ally responding to exogenous GnRH (Seminara et al., 2003)
shows the receptor is not absolutely required for this pituitaryCELL METABOLISM : MAY 2005
M I N I R E V I E WFigure 2. Potential endocrine and paracrine actions of kisspeptin-GPR54 signaling
The schematic shows the hypothalamic-pituitary-gonadal axis and a possible peripheral source of kisspeptins, for example, placenta or an epithelial tumor with
amplification of the kiss-1 locus. Locally secreted kisspeptins act to regulate trophoblast invasion (placenta) or, in tumors also expressing GPR54, to suppress tumor
cell migration. Kisspeptins derived from either source could circulate directly to act at the hypothalamic level to stimulate GnRH release and so increase gonadotropic
drive of sex steroid production.function. However, this does not exclude that some potentia-
tion or coregulation could occur in gonadotropes. In the human
GPR54-deficient patient studied after normalization of the pitu-
itary axis with exogenous pulsatile GnRH, the dose-response
curve was left shifted with respect to normal. Data from iso-
lated pituitary and isolated pituicyte preparations are conflict-
ing. No evidence for a direct LH/FSH release effect has been
seen (consistent with the genetic data); however, possible po-
tentiation of GnRH responses have been noted in some studies.
Resolution of these questions will likely await cell type-specific
knockouts of these receptors and formal tests of cell autonomy
in the pituitary and hypothalamus.
Body mass and nutritional inputs to the hypothalamus are
known to be important in determining the onset of puberty. For
example, absence of leptin signaling (either receptor or peptide
mutants) results in obesity and hypothalamic hypogonadism.
Although leptin does not itself appear to be a major driver of
GnRH release, the presence of leptin signaling appears to be
required for normal GnRH release. Therefore, another key
question posed by the hypothalamic mechanism for GPR54 is
whether receptor signaling is epistatic to other signals such asCELL METABOLISM : MAY 2005leptin and NMDA. A recent study noted that, in a starvation
model of leptin deficiency and also following leptin immunode-
pletion, kisspeptin administration still results in robust gonado-
tropin release (Navarro et al., 2004b), implying that GPR54 sig-
naling is not epistatic to leptin signaling and can functional in
parallel. However, it is unclear whether the regime of kisspeptin
administration in these model systems reflects physiological as
opposed to pharmacological levels of kisspeptin. Furthermore,
it leaves open the important question of whether kisspeptin
secretion may itself be regulated via leptin signaling.
Finally, the new endocrinology of kisspeptins may also have
some twists to offer in the area of cancer biology. Pharmaco-
logical manipulation of the hypothalamic-pituitary-gonadal axis
is a major point of therapeutic intervention for sex steroid-
driven tumors, and blockade of GPR54 could offer further op-
portunities. However, significant additional actions of kisspep-
tin-GPR54 signaling are known. The kisspeptin ligands for
GPR54 were independently identified some years ago in micro-
cell-mediated chromosome transfer screens (Lee and Welch,
1997) for metastasis suppressing factors in melanoma and
breast carcinoma cells. There is good cell biological evidence295
M I N I R E V I E Wthat, in the relevant context, GPR54 signaling results in sup-
pression of migratory behavior (Ohtaki et al., 2001) (kisspeptin-
54 is also known as metastin, from these properties), probably
via the induction of focal adhesion kinases that induce cells to
stick down. There is also clear evidence for this as a mecha-
nism in the physiological regulation of trophoblast invasion (Bil-
ban et al., 2004) during placental development, and, further-
more, in cell lines manipulated to express GPR54, kisspeptin
administration suppresses in vivo metastatic activity. The rele-
vance of this for human tumors remains unclear—clinical
studies of amplification and loss of KISS1 and GPR54 have
reported conflicting results and with small numbers of tumors
studied (Dhar et al., 2004; Ringel et al., 2002) in relation to
clinical outcomes. However, that some tumors may overex-
press KISS1 and GPR54 is known, and this raises the intriguing
possibility (Figure 2) that, for some sex steroid-driven epithelial
tumors (breast, ovarian, and prostate carcinoma), an element
of host-derived hormonal drive could come from the tumor
cells secreting kisspeptins that in turn drive the hypothalamic
axis. In such cases, behavior of the tumor cells could derive
from a complex interplay of host hormonal drive, tumor cell
hormone receptor status, and local paracrine effects on cell
migration. According to this speculative model, steroid recep-
tor +ve, kisspeptin +ve but GPR54-deficient tumors might be
predicted to have more aggressive behavior than kisspeptin-
producing, GPR54+ve, steroid receptor −ve tumors. Large-
scale studies of these loci in epithelial tumors are required to
address this hypothesis.
The role of kisspeptins and GPR54 in regulation of the GnRH
axis places these proteins as central to the biology of sex ste-
roids and associated diseases and suggests a number of im-
portant new avenues for therapeutic intervention. Resolving
the details of the mechanisms implied over the next few years
will most certainly be a fascinating voyage of discovery.
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